United States · FDA National Drug Code directory
Xofluza
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 50242-599_c2da90f4-a11c-46d2-be18-53d286b084cf
- Product NDC
- 50242-599
- Form
- GRANULE, FOR SUSPENSION
- Composition / generic term
- Baloxavir Marboxil
- Labeler
- Genentech, Inc.
- Marketing category
- NDA
- Marketing start / end (source format)
- 20250530
- Source listing expiry
- 20261231
Source-listed ingredients
- BALOXAVIR MARBOXIL — 30 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 1 PACKET in 1 CARTON (50242-599-01) / 1 GRANULE, FOR SUSPENSION in 1 PACKET · 50242-599-01
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →